Bell's Palsy - Forecast in 15 Major Markets 2017-2027 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Bell's Palsy Forecast in 15 Major Markets 2017-2027" report to their offering.

Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side of the face caused by the compression of the facial/cranial nerve, with no known underlying pathological cause. Such a condition typically manifests in a unilateral paralysis of the face. In rare cases, both sides of the face can be affected. Bell's palsy is characterized by its rapid onset, reaching clinical peak within 72 hours. Most patients fully recover from Bell's palsy.

This report provides the current incident population for Bell's palsy across 15 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, China, Turkey, Mexico, Denmark, Egypt and South Korea) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Reasons to Buy:

  • Able to quantify patient populations in global Bell's palsy market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Bell's palsy and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Bell's palsy incident population.
  • Identify sub-populations within Bell's palsy which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Bell's palsy patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line incidence for Bell's palsy

10. Features of Bell's palsy patients

11. Recurrence of Bell's palsy

12. Sequelae and features of Bell's palsy patients

13. Co-morbidities of patients with Bell's palsy

14. Abbreviations used in the report

15. Patient-Based Offering

16. Online Pricing Data and Platforms

17. References

18. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/6mv958/bells_palsy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs